Blood-based tests for multicancer early detection (PATHFINDER): a prospective cohort study D Shrag et al. The Lancet, October 7, 2023

From the abstract: "Multicancer early detection (MCED) blood tests can detect a cancer signal from circulating cell-free DNA (cfDNA). PATHFINDER was a prospective cohort study investigating the feasibility of MCED testing for cancer screening. In this prospective cohort study done in oncology and primary care outpatient clinics at seven US health networks, a convenience sample of adults aged 50 years or older without signs or symptoms of cancer consented to MCED testing. The study supports the feasibility of MCED screening for cancer and underscores the need for further research investigating the test's clinical utility. " https://phgkb.cdc.gov/PHGKB/phgHome.action?query=Liquid%20biopsy&action=search&Mysubmit=Search